A woman being treated with<unk>  chemotherapy for breast cancer. Cold mittens and wine coolers are placed on her hands and feet to prevent deleterious effects on the nails. Similar strategies can be used to prevent hair loss.<unk>  is used in the treatment of various cancers, including breast, lung, prostate, gastric, head and neck, and ovarian cancer. Clinical data have shown<unk>  to have cytotoxic activity against breast, colorectal, lung, ovarian, prostate, liver, renal, gastric, and head and neck cancers and melanoma. In hormone-refractory prostate cancer<unk>  improves life expectancy and overall life quality. The optimal dose scheduling of taxanes remains unconfirmed, but most studies find significant mortality benefit following either a three-week or a one-week administration schedule. While a 2010 article in Current Clinical Pharmacology states, "weekly administration has emerged as the optimal schedule," the official<unk>  package insert recommends administration every three weeks. Outcomes Treatment with<unk>  increases survival time in people with certain types of cancer. While some clinical trials show median survival times to be increased by approximately only three months, the range of survival time is large. Many people survive beyond five years with treatment from<unk> , however it is difficult to attribute these findings directly to treatment with<unk> . Improved median survival time and response indicates that<unk>  slows metastatic cancer progression and can lead to disease-free survival. Conjunctive treatment of prednisone with<unk>  has been shown to lead to improved survival rate as well as improved quality of life and reduction of pain compared with treatments with mitoxantrone. As well as inhibiting mitosis, the presence of<unk>  has been found to lead to the phosphorylation of the oncoprotein bcl-2, which leads to apoptosis of cancer cells that had previously blocked the apoptotic inducing mechanism, leading to tumour regression. Enhanced effects of radiation therapy when combined with<unk>  has been observed in mice.<unk>  has also been found to have greater cellular uptake and is retained longer intracellularly than paclitaxel allowing<unk>  treatment to be effective with a smaller dose, leading to fewer and less severe adverse effects. Breast cancer<unk>  and paclitaxel have comparable efficacy metastatic breast cancer but paclitaxel has less severe side effects. Additionally, it has been noted that<unk>  is prone to cellular drug resistance via a variety of different mechanisms. Monitoring and combination use<unk>  is administered via a one-hour infusion every three weeks over ten or more cycles. Treatment is given under the supervision of an oncologist. Strict monitoring of blood cell counts, liver function, serum electrolytes, serum creatinine, heart function, oxygen saturation and fluid retention is required detect adverse reactions and toxicity so that treatment can be modified or terminated if necessary. Premedication with corticosteroids is recommended before each administration of<unk>  to reduce fluid retention and hypersensitive reactions. Other medications will often be given to aid pain management and other symptoms. The treatment of breast cancer with doxorubicin and cyclophosphamide is enhanced by adjuvant treatment with<unk> .<unk>  is also used in combination with capecitabine, a DNA synthesis inhibitor.
Docetaxel
Paclitaxel
Doxorubicin
Trastuzumab
Ifosfamide
Lipoplatin
Ribociclib
Cabazitaxel